Investigators in Boston say that by measuring the androgen receptor signaling pathway they can decide on the ideal treatment for patients with metastatic prostate cancer that stops responding to initial therapy. John Schieszer has the story in today’s Medical Minute.

Topics:

Prostate Cancer